A phase Ib/II combination trial of PU-H71 in patients with myelofibrosis

Trial Profile

A phase Ib/II combination trial of PU-H71 in patients with myelofibrosis

Planning
Phase of Trial: Phase I/II

Latest Information Update: 06 Apr 2017

At a glance

  • Drugs PU H71 (Primary)
  • Indications Myelofibrosis
  • Focus Adverse reactions
  • Sponsors Samus Therapeutics
  • Most Recent Events

    • 06 Apr 2017 New trial record
    • 30 Mar 2017 According to a Samus Therapeutics media release, the company expects to file an Investigative New Drug (IND) application for PU-H71 in the treatment of myelofibrosis in the second quarter of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top